NCT06233942 2026-03-18
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
72 trialsNCT06598800 2026-03-12
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT05981703 2026-03-04
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06589596 2026-03-04
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT04855656 2026-02-27
MYTHIC
Debiopharm International SA
Phase 1 Recruiting
NCT06625593 2026-02-20
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06750185 2026-02-11
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
BioNTech SE
Phase 1 Recruiting
NCT07182591 2026-02-03
A Study of DS5361b in Participants With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Recruiting
NCT06260514 2026-01-26
ACESOT-1051
Aprea Therapeutics
Phase 1 Recruiting
NCT06302426 2026-01-16
Trial of INI-4001 in Patients With Advanced Solid Tumours
Inimmune Corporation
Phase 1 Recruiting
NCT06859762 2026-01-14
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1 Recruiting
NCT06298058 2026-01-07
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT06512116 2026-01-07
A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT05007782 2025-12-29
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT05306132 2025-12-23
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06143774 2025-12-17
Study of TRX-920 for Patients With Advanced Solid Tumors
TaiRx, Inc.
Phase 1 Recruiting
NCT06241456 2025-12-09
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT05547321 2025-11-25
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Oncomatryx Biopharma S.L.
Phase 1 Recruiting
NCT04999384 2025-11-18
First in Human, Dose Escalation Study of AN4005
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Recruiting
NCT06258408 2025-11-17
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
Broadenbio Ltd., Co.
Phase 1 Recruiting
NCT06597721 2025-11-13
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Adcendo ApS
Phase 1 Recruiting
NCT07098299 2025-11-06
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
Barbara Ann Karmanos Cancer Institute
Phase 1 Recruiting
NCT06672185 2025-10-24
ARC101 in Advanced Solid Tumors
Third Arc Bio
Phase 1 Recruiting
NCT06130254 2025-10-14
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06126666 2025-10-01
A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
ABL Bio, Inc.
Phase 1 Recruiting
NCT05841563 2025-09-24
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
PharmaMar
Phase 1 Recruiting
NCT05725291 2025-08-17
AMT-116 in Patients With Advanced Solid Tumors
Multitude Therapeutics Inc.
Phase 1 Recruiting
NCT06487455 2025-08-17
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1 Recruiting
NCT05906862 2025-08-14
AMT-253 in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics Inc.
Phase 1 Recruiting
NCT05279300 2025-08-11
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
CStone Pharmaceuticals
Phase 1 Recruiting
NCT07110883 2025-08-08
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1 Recruiting
NCT06220838 2025-07-29
Study SC-101 in Subjects With Advanced Malignancies
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1 Recruiting
NCT05687682 2025-06-18
Safety of AM-928 Infusion in Advanced Solid Tumors
AcadeMab Biomedical Inc.
Phase 1 Recruiting
NCT06304571 2025-05-06
A Study of HC006 in Subjects With Advanced Solid Tumors
HC Biopharma Inc.
Phase 1 Recruiting
NCT04998422 2025-03-13
A Study of HG381 Administered to Patients With Advanced Solid Tumors
HitGen Inc.
Phase 1 Recruiting
NCT06220864 2025-03-13
SNV1521 in Participants with Advanced Solid Tumors
Synnovation Therapeutics, Inc.
Phase 1 Recruiting
NCT05036291 2025-03-05
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
Ningbo Newbay Technology Development Co., Ltd
Phase 1 Recruiting
NCT06352359 2025-03-05
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
OncoC4, Inc.
Phase 1 Recruiting
NCT06035744 2025-03-03
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Cullinan Therapeutics Inc.
Phase 1 Recruiting
NCT04762641 2025-02-06
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
ABL Bio, Inc.
Phase 1 Recruiting
NCT05789602 2025-01-27
A Study of BPI-460372 in Advanced Solid Tumor Patients
Betta Pharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT06772415 2025-01-22
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06404905 2024-12-27
BT02
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1 Recruiting
NCT06084286 2024-11-19
Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
Sichuan University
Phase 1 Recruiting
NCT05772455 2024-10-28
A Study of XZB-0004 in Patients With Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04093466 2024-10-17
A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06632574 2024-10-09
A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Recruiting
NCT04740398 2024-08-28
A Study of CBP-1008 in Patients With Advanced Solid Tumor
Coherent Biopharma (Suzhou) Co., Ltd.
Phase 1 Recruiting
NCT06404281 2024-08-22
γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors
Changzhou No.2 People's Hospital
Phase 1 Recruiting
NCT06257680 2024-07-31
A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
Aeonvital Biomedicine
Phase 1 Recruiting